Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 9/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725448 | 0.90 | PDE2A (0.55) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12735210 | 0.87 | PDE2A (0.50) | PDE2ACYP2D6CYP2C19KCNH2NPSR1 | |
| SCHEMBL18896301 | 0.84 | PDE2A (0.65) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15156685 | 0.83 | PDE2A (0.58) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2629463 | 0.79 | PDE2A (0.73) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18638207 | 0.78 | PDE2A (0.61) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6644323 | 0.77 | PDE2A (0.65) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18075371 | 0.76 | PDE2A (1.00) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21180451 | 0.76 | PDE2A (0.69) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL20072514 | 0.76 | PDE2A (0.69) | PDE2ACYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | PDE2A 1206/4885CYP1A2 1383/4885CYP2D6 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.